Osamu Okada - HUTCHMED DRC Director
| HCM Stock | USD 18.41 0.16 0.88% |
Director
Mr. Osamu Okada was serving as Director in Hitachi Construction Machinery Co. Ltd. since June 2013. He is also a member of Audit Committee in the Company. He joined the Company in April 1979 and used to serve as Director of Service Business in Main Sales Supervision Unit and Manager of Human Resources Development Center in the Company. since 2013.
| Age | 59 |
| Tenure | 11 years |
| Address | Cheung Kong Center, Hong Kong, Hong Kong |
| Phone | 852 2121 8200 |
| Web | https://www.hutch-med.com |
HUTCHMED DRC Management Efficiency
As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.08. Also, Return On Capital Employed is likely to grow to 0.02. At this time, HUTCHMED DRC's Return On Assets are very stable compared to the past year. HUTCHMED DRC's management efficiency ratios could be used to measure how well HUTCHMED DRC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Meredith Kaya | Ironwood Pharmaceuticals | N/A | |
| Christopher Walsh | Ironwood Pharmaceuticals | 71 | |
| Sean Keenan | Regencell Bioscience Holdings | 41 | |
| Julie McHugh | Ironwood Pharmaceuticals | 60 | |
| Charles Brymer | Regencell Bioscience Holdings | 56 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Alex Yemenidjian | Regencell Bioscience Holdings | 60 | |
| Michael Ross | Deciphera Pharmaceuticals LLC | 68 | |
| George Ireland | Regencell Bioscience Holdings | 56 | |
| Peter Ball | Regencell Bioscience Holdings | N/A | |
| Robert Nostrand | Intracellular Th | 61 | |
| Tracy Marshbanks | ANI Pharmaceuticals | 52 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Dennis Winger | Pacira Pharmaceuticals | 68 | |
| Stephen Kaplan | Regencell Bioscience Holdings | 57 | |
| David Keyte | Regencell Bioscience Holdings | 59 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| Patrick Heron | Collegium Pharmaceutical | 44 | |
| Natale Ricciardi | Prestige Brand Holdings | 71 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.01 |
HUTCHMED DRC Leadership Team
Elected by the shareholders, the HUTCHMED DRC's board of directors comprises two types of representatives: HUTCHMED DRC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED DRC's management team and ensure that shareholders' interests are well served. HUTCHMED DRC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED DRC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eishi Fukumoto, Executive Officer, Chief Director of Research | ||
| Tetsuo Katsurayama, Executive Officer, Chief Director of Finance | ||
| Genroku Sugiyama, Executive Officer, Director of India Business | ||
| Shigeru Endo, Non-Executive Director | ||
| Selina Zhang, Senior Resources | ||
| Graeme Jack, Independent Non-Executive Director | ||
| Masato Tamaki, Executive Officer, CIO, Chief Director of IT Promotion | ||
| Koji Sumioka, Executive Officer, Director of Japan Business and Presidentident of Subsidiary | ||
| Simon To, Executive Chairman of the Board | ||
| Hong Chen, Senior China | ||
| Kenji Ohta, Executive Officer, Deputy Chief Director of Sales, Chief Director of Life Cycle Support Business | ||
| Paul Carter, Senior Independent Non-Executive Director | ||
| Edith Shih, Company Secretary, Non-Executive Director | ||
| Yasushi Ochiai, Managing Executive Officer, Chief Director of Sales | ||
| Tsutomu Mizutani, Senior Managing Executive Officer, Director of China Business, Director | ||
| Takashi Kawamura, Independent Chairman of the Board of Directors | ||
| BSE CS, Company Director | ||
| Toshihiro Ohno, Executive Officer, Chief Director of Development, Chief Director of PDI | ||
| Osamu Okada, Director | ||
| ACGI BSc, Ex Chairman | ||
| Yukio Arima, Senior Managing Executive Officer, Chief Director of Strategy Planning, Chief Director of Business Administration, Director | ||
| Chig Cheng, CFO, Executive Director | ||
| Mitsuhiro Tabei, Managing Executive Officer, Chief Director of Marketing, Director | ||
| CA BEc, CFO Director | ||
| CS CGP, Company Director | ||
| Christian Salbaing, Non-Executive Director | ||
| Christian Hogg, CEO, Executive Director | ||
| Weiguo Su, Executive Director | ||
| Karen Atkin, Executive COO | ||
| Hisashi Hasegawa, Executive Officer, Chief Human Resource Officer, Chief Director of Human Resources | ||
| Kotaro Hirano, Executive Officer, Chief Director of Business Administration | ||
| Hiroshi Tokushige, Executive Vice President Representative Executive Officer, Chief Director of Export Management, Leader of C Project, Director | ||
| Christopher Nash, Senior Independent Non-Executive Director | ||
| Akihiko Hiraoka, Managing Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary | ||
| Takayoshi Ikeda, Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary | ||
| Shigeru Azuhata, Independent Director | ||
| Kin MBA, Senior Communications | ||
| Michifumi Tabuchi, Executive Officer, Director of China Business, General Manager of Subsidiary | ||
| Takuro Sato, Director of Legal Affairs | ||
| Charles Nixon, Group Counsel | ||
| Qingmei Wang, Senior Alliances | ||
| Karen Ferrante, Non-Executive Independent Director | ||
| Yuichi Tsujimoto, Executive President Representative Executive Officer, Director | ||
| Shu Mok, Non-Executive Independent Director | ||
| Michael Howell, Independent Non-Executive Director | ||
| Christopher Huang, Independent Non-Executive Director | ||
| David Ng, Head Strategies | ||
| Dan Eldar, Non-Executive Director | ||
| Tadashi Motoi, Executive Officer, Deputy Chief Director of Asian & Oceanian Business and Presidentident of Subsidiary | ||
| Hideto Mitamura, Independent Director | ||
| Weiguo BSc, Chief CEO | ||
| Morio Sumiya, Executive Officer, Director of Europe & Middle East Business and Presidentident of Subsidiary |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED DRC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.01 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 30.37 B | ||||
| Shares Outstanding | 170.73 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 9.43 % | ||||
| Number Of Shares Shorted | 501.45 K | ||||
| Price To Earning | 335.94 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.Note that the HUTCHMED DRC information on this page should be used as a complementary analysis to other HUTCHMED DRC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for HUTCHMED Stock analysis
When running HUTCHMED DRC's price analysis, check to measure HUTCHMED DRC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED DRC is operating at the current time. Most of HUTCHMED DRC's value examination focuses on studying past and present price action to predict the probability of HUTCHMED DRC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED DRC's price. Additionally, you may evaluate how the addition of HUTCHMED DRC to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is HUTCHMED DRC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.6 | Revenue Per Share 4.93 | Quarterly Revenue Growth 0.36 | Return On Assets 0.01 | Return On Equity 0.1465 |
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.